吉西他滨联合高强度聚焦超声治疗中晚期胰腺癌的临床观察  

A Clinical Study of Gemcitabine Combined with High Intensity Focused Ultrasound Treatment for Advanced Pancreatic Cancer

作　　者：雷小林[1] 林远洪[1] 段廷旺[1] 李铁莲[1] 

机构地区：[1]攀枝花学院附属医院肿瘤科,四川攀枝花617000

出　　处：《肿瘤预防与治疗》2011年第2期74-76,共3页Journal of Cancer Control And Treatment

摘　　要：目的:探讨吉西他滨联合高强度聚焦超声(HIFU)治疗中晚期胰腺癌的疗效和安全性。方法:64例中晚期胰腺癌患者随机分为两组,A组:高强度聚焦超声治疗;B组:吉西他滨联合高强度聚焦超声治疗,比较两组的疗效、临床受益率和不良反应。结果:A组有效率43.8%、B组75.0%(P<0.05),A组临床受益率56.3%,B组84.4%(P<0.05);B组6个月、12个月生存率分别高于A组;两组不良反应差异无统计学意义(P>0.05)。结论:吉西他滨联合高强聚焦超声治疗中晚期胰腺癌具有更好的疗效。Objective： To investigate the effect and safety of gemcitabine combined with higb intensity focused ultrasound（ HI- FU） treatment for advanced pancreatic cancer. Methods： 64 patients with advanced pancreatic cancer were randomly divided into group A （ H/FU only） and group B（ Gemcitabine ＋ HIFU）, the effect ,clinical benefit rates and adverse reactions were compared. Re- suits ： The effective rates in group A and group B were 43.8% and 75.0% respectively（ P 〈 0. 05 ）. The clinical benefit rates in group A and group B were 56.3% and 84. 4% respectively（ P 〈 0. 05）. Survival time of group B were longer than group A;There was no significant difference of adverse reactions between the two groups（ P 〉 0. 05 ）. Conclusion： Therapy of Gemcitabine combined with HIFU was more effective than HIFU only in the treatment of advanced pancreatic cancer.

关 键 词：吉西他滨 高强度聚焦超声 胰腺癌 

分 类 号：R735.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]